abstract |
The invention relates to the utilization of given EGF-receptor antagonists for the production of a medicament to prevent and/or treat benign prostatic hyperplasia and/or prostatic hypertrophy, to a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy involving the administration of an EGF-receptor antagonist of groups (A), (B) or (C), optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, and to the corresponding pharmaceutical compositions. |